Anzeige
Meldung des Tages: Gold dreht wieder auf: Goldpreis-Comeback – und diese Bohrung liefert 307 Meter „Gold-System“

Idorsia Aktie News

Aktie
WKN:  A2DTEB ISIN:  CH0363463438 US-Symbol:  IDRSF Branche:  Biotechnologie Land:  Schweiz
3,62 CHF
+0,00 CHF
0,00%
3,9512 € 17:18:07 Uhr
Depot/Watchlist
Marktkapitalisierung *
858,56 Mio. €
Streubesitz
55,25%
KGV
-0,58
Dividende
32,59 €
Dividendenrendite
-   %
Index-Zuordnung
-

Idorsia News

01.09.25 - GlobeNewswire
Idorsia furthers the science of sleep and insomnia at World Sleep 2025
Allschwil, Switzerland – September 1, 2025 Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster ...
28.08.25 - GlobeNewswire
Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension
Allschwil, Switzerland – August 28, 2025 Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy ...
27.08.25 - GlobeNewswire
Idorsia successfully completes convertible bonds restructuring
Ad hoc announcement pursuant to Art. 53 LR
19.08.25 - GlobeNewswire
TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension
The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the endothelin pathway. Endothelin is upregulated in ...
19.08.25 - GlobeNewswire
Idorsia publishes end results of repurchase offer for its 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR
12.08.25 - GlobeNewswire
TRYVIO nominated for the 2025 Prix Galien USA “Best Pharmaceutical Product”
Allschwil, Switzerland – August 12, 2025 Idorsia Ltd (SIX: IDIA) announced today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life ...
11.08.25 - GlobeNewswire
Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR
30.07.25 - GlobeNewswire
Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results
Ad hoc announcement pursuant to Art. 53 LR
23.07.25 - GlobeNewswire
Invitation to Idorsia's HY 2025 Financial Reporting webcast and conference call with our new CEO Srishti Gupta
Idorsia will publish its Half Year 2025 Financial Reporting on Wednesday July 30, at 07:00 CEST.
30.06.25 - GlobeNewswire
A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans
Ad hoc announcement pursuant to Art. 53 LR
25.06.25 - GlobeNewswire
Bondholders approve amended terms of the 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR
25.06.25 - GlobeNewswire
Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR
23.06.25 - GlobeNewswire
Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
Ad hoc announcement pursuant to Art. 53 LR
10.06.25 - GlobeNewswire
Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia
Ad hoc announcement pursuant to Art. 53 LR
06.06.25 - GlobeNewswire
Idorsia publishes invitations to bondholder meetings
Ad hoc announcement pursuant to Art. 53 LR
28.05.25 - GlobeNewswire
Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025
Allschwil, Switzerland – May 28, 2025 At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all ...
21.05.25 - GlobeNewswire
New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability
Ad hoc announcement pursuant to Art. 53 LR
02.05.25 - GlobeNewswire
Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders
Allschwil, Switzerland – May 2, 2025 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of ...
30.04.25 - GlobeNewswire
Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset
Ad hoc announcement pursuant to Art. 53 LR
29.04.25 - GlobeNewswire
New data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine
Daridorexant improved sleep maintenance throughout the entire night, including the last quarter, while also improving next-​morning sleepiness. Daridorexant improved next-...

Newssuche

Videos

newspaper
20:00 Uhr
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »